vs
Side-by-side financial comparison of ARDELYX, INC. (ARDX) and GETTY REALTY CORP (GTY). Click either name above to swap in a different company.
ARDELYX, INC. is the larger business by last-quarter revenue ($94.5M vs $57.8M, roughly 1.6× GETTY REALTY CORP). GETTY REALTY CORP runs the higher net margin — 46.0% vs -39.8%, a 85.8% gap on every dollar of revenue. On growth, ARDELYX, INC. posted the faster year-over-year revenue change (27.5% vs 10.5%). Over the past eight quarters, ARDELYX, INC.'s revenue compounded faster (13.6% CAGR vs 7.6%).
Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.
Getty Realty Corp is a publicly traded real estate investment trust (REIT) headquartered in the United States. It owns, leases, and manages a diversified portfolio of commercial real estate assets, primarily consisting of convenience stores, fuel stations, and adjacent retail locations across U.S. states, serving tenants across retail and energy sectors.
ARDX vs GTY — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $94.5M | $57.8M |
| Net Profit | $-37.6M | $26.6M |
| Gross Margin | — | — |
| Operating Margin | — | 66.1% |
| Net Margin | -39.8% | 46.0% |
| Revenue YoY | 27.5% | 10.5% |
| Net Profit YoY | — | 80.1% |
| EPS (diluted) | $-0.15 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $94.5M | $57.8M | ||
| Q4 25 | $125.2M | $60.5M | ||
| Q3 25 | $110.3M | $55.6M | ||
| Q2 25 | $97.7M | $53.3M | ||
| Q1 25 | $74.1M | $52.3M | ||
| Q4 24 | $116.1M | $53.0M | ||
| Q3 24 | $98.2M | $51.5M | ||
| Q2 24 | $73.2M | $49.9M |
| Q1 26 | $-37.6M | $26.6M | ||
| Q4 25 | $-407.0K | $27.0M | ||
| Q3 25 | $-969.0K | $23.3M | ||
| Q2 25 | $-19.1M | $14.0M | ||
| Q1 25 | $-41.1M | $14.8M | ||
| Q4 24 | $4.6M | $22.3M | ||
| Q3 24 | $-809.0K | $15.3M | ||
| Q2 24 | $-16.5M | $16.7M |
| Q1 26 | — | — | ||
| Q4 25 | 91.3% | — | ||
| Q3 25 | 96.4% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.4% | — | ||
| Q4 24 | 84.3% | — | ||
| Q3 24 | 84.0% | — | ||
| Q2 24 | 87.1% | — |
| Q1 26 | — | 66.1% | ||
| Q4 25 | 4.1% | 67.3% | ||
| Q3 25 | 4.2% | 62.5% | ||
| Q2 25 | -14.7% | 46.7% | ||
| Q1 25 | -49.0% | 50.5% | ||
| Q4 24 | 7.0% | 61.6% | ||
| Q3 24 | 2.3% | 48.9% | ||
| Q2 24 | -18.6% | 52.5% |
| Q1 26 | -39.8% | 46.0% | ||
| Q4 25 | -0.3% | 44.7% | ||
| Q3 25 | -0.9% | 42.0% | ||
| Q2 25 | -19.5% | 26.3% | ||
| Q1 25 | -55.5% | 28.3% | ||
| Q4 24 | 4.0% | 42.1% | ||
| Q3 24 | -0.8% | 29.8% | ||
| Q2 24 | -22.5% | 33.5% |
| Q1 26 | $-0.15 | $0.43 | ||
| Q4 25 | $-0.01 | $0.46 | ||
| Q3 25 | $0.00 | $0.40 | ||
| Q2 25 | $-0.08 | $0.24 | ||
| Q1 25 | $-0.17 | $0.25 | ||
| Q4 24 | $0.01 | $0.38 | ||
| Q3 24 | $0.00 | $0.27 | ||
| Q2 24 | $-0.07 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.1M | $3.7M |
| Total DebtLower is stronger | $203.5M | — |
| Stockholders' EquityBook value | $148.6M | — |
| Total Assets | $504.5M | $2.2B |
| Debt / EquityLower = less leverage | 1.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $238.1M | $3.7M | ||
| Q4 25 | $68.0M | $8.4M | ||
| Q3 25 | $42.7M | $5.2M | ||
| Q2 25 | $90.0M | $7.5M | ||
| Q1 25 | $30.8M | $6.3M | ||
| Q4 24 | $64.9M | $9.5M | ||
| Q3 24 | $47.4M | $4.0M | ||
| Q2 24 | $41.9M | $4.7M |
| Q1 26 | $203.5M | — | ||
| Q4 25 | $202.8M | $995.0M | ||
| Q3 25 | $202.1M | $934.6M | ||
| Q2 25 | $201.4M | $919.2M | ||
| Q1 25 | $151.3M | $901.4M | ||
| Q4 24 | $150.9M | $904.3M | ||
| Q3 24 | $100.7M | $833.9M | ||
| Q2 24 | $100.2M | $838.4M |
| Q1 26 | $148.6M | — | ||
| Q4 25 | $166.9M | $1.1B | ||
| Q3 25 | $154.3M | $1.0B | ||
| Q2 25 | $139.5M | $982.4M | ||
| Q1 25 | $145.7M | $961.1M | ||
| Q4 24 | $173.3M | $962.1M | ||
| Q3 24 | $158.3M | $963.4M | ||
| Q2 24 | $147.0M | $951.0M |
| Q1 26 | $504.5M | $2.2B | ||
| Q4 25 | $501.6M | $2.2B | ||
| Q3 25 | $486.2M | $2.1B | ||
| Q2 25 | $466.8M | $2.0B | ||
| Q1 25 | $410.2M | $2.0B | ||
| Q4 24 | $435.8M | $2.0B | ||
| Q3 24 | $367.9M | $1.9B | ||
| Q2 24 | $343.5M | $1.9B |
| Q1 26 | 1.37× | — | ||
| Q4 25 | 1.21× | 0.93× | ||
| Q3 25 | 1.31× | 0.92× | ||
| Q2 25 | 1.44× | 0.94× | ||
| Q1 25 | 1.04× | 0.94× | ||
| Q4 24 | 0.87× | 0.94× | ||
| Q3 24 | 0.64× | 0.87× | ||
| Q2 24 | 0.68× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
GTY
Segment breakdown not available.
